Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study

European Urology

Volumn 65, Issue 6, 2014, Pages 1058-1066

  Culp, Stephen H ^a   Schellhammer, Paul F ^b   Williams, Michael B ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Brachytherapy; Metastatic prostate cancer; Outcomes assessment; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; COMORBIDITY; DISEASE SPECIFIC SURVIVAL; FOLLOW UP; HUMAN; LOCAL THERAPY; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC PROSTATE CANCER; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PELVIS LYMPH NODE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SYSTEMIC THERAPY; ADENOCARCINOMA; BLOOD; CANCER GRADING; CANCER REGISTRY; CANCER STAGING; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY; SURVIVAL RATE;

ADENOCARCINOMA; AGE FACTORS; AGED; BRACHYTHERAPY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEER PROGRAM; SURVIVAL RATE;

EID: 84899497112     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.11.012     Document Type: Article

References (30)

1. P. Scardino Update: NCCN prostate cancer clinical practice guidelines JNCCN 3 Suppl 1 2005 S29 S33
2. D.A. Loblaw, K.S. Virgo, and R. Nam et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline J Clin Oncol 25 2007 1596 1605
3. O. Glehen, F. Mohamed, and F.N. Gilly Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia Lancet Oncol 5 2004 219 228
4. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259
5. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 352 1998 930 942
6. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659
7. G.H. Mickisch, A. Garin, H. van Poppel, L. de Prijck, and R. Sylvester Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970
8. T. Nitta, and K. Sato Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas Cancer 75 1995 2727 2731
9. L.K. Temple, L. Hsieh, W.D. Wong, L. Saltz, and D. Schrag Use of surgery among elderly patients with stage IV colorectal cancer J Clin Oncol 22 2004 3475 3484
10. L.C. Harlan, and B.F. Hankey The surveillance, epidemiology, and end-results program database as a resource for conducting descriptive epidemiologic and clinical studies J Clin Oncol 21 2003 2232 2233
11. F.L. Greene, D.L. Page, and I.D. Fleming et al. AJCC cancer staging handbook: TNM classification of malignant tumors ed. 6. 2002 Springer-Verlag New York, NY
12. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
13. M.R. Humphreys, K.A. Fernandes, and S.S. Sridhar Impact of age at diagnosis on outcomes in men with castrate-resistant prostate cancer (CRPC) J Cancer 4 2013 304 314
14. E. Scosyrev, E.M. Messing, S. Mohile, D. Golijanin, and G. Wu Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality Cancer 118 2012 3062 3070
15. V. Bertaglia, M. Tucci, and C. Fiori et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer Clin Genitourin Cancer 11 2013 325 330
16. C.J. Ryan, E.P. Elkin, E.J. Small, J. Duchane, and P. Carroll Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from PCaSURE Urol Oncol 24 2006 396 402
17. E.J. Small, P.F. Schellhammer, and C.S. Higano et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 2006 3089 3094
18. J.S. de Bono, C.J. Logothetis, and A. Molina et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
19. J.S. de Bono, S. Oudard, and M. Ozguroglu et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
20. H.I. Scher, K. Fizazi, and F. Saad et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
21. American Cancer Society Cancer facts and figures 2013 2013 American Cancer Society Atlanta, GA
22. T. Steuber, L. Budaus, and J. Walz et al. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study BJU Int 107 2011 1755 1761
23. R. Ghavamian, E.J. Bergstralh, M.L. Blute, J. Slezak, and H. Zincke Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison J Urol 161 1999 1223 1227 discussion 1227-8
24. J. Engel, P.J. Bastian, and H. Baur et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer Eur Urol 57 2010 754 761
25. G.P. Swanson, M. Riggs, and J. Earle Failure after primary radiation or surgery for prostate cancer: differences in response to androgen ablation J Urol 172 2004 525 528
26. I.M. Thompson, C. Tangen, J. Basler, and E.D. Crawford Impact of previous local treatment of prostate cancer on subsequent metastatic disease J Urol 168 2002 1008 1012
27. P.W. Kantoff, C.S. Higano, and N.D. Shore et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
28. E. Comen, L. Norton, and J. Massague Clinical implications of cancer self-seeding Nat Rev Clin Oncol 8 2011 369 377
29. L. Resel Folkersma, L. San Jose Manso, I. Galante Romo, J. Moreno Sierra, and C. Olivier Gomez Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer Urology 80 2012 1328 1332
30. P. Warde, M. Mason, and K. Ding et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Lancet 378 2011 2104 2111